Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

Christian Rolfo*, Nicolas Isambert, Antoine Italiano, L. Rhoda Molife, Jan Hm Schellens, Jean-Yves Blay, Thomas Decaens, Rebecca Kristeleit, Olivier Rosmorduc, Regina Demlova, Myung-Ah Lee, Alain Ravaud, Katerina Kopeckova, Maria Learoyd, Wendy Bannister, Gershon Locker, Judith de Vos-Geelen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1807-1818
Number of pages12
JournalBritish Journal of Clinical Pharmacology
Volume86
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • advanced solid tumours
  • hepatic impairment
  • liver
  • olaparib
  • pharmacokinetics
  • poly(ADP-ribose) polymerase
  • safety
  • DRUG
  • FORMULATION
  • INHIBITOR
  • DISEASE
  • CANCER

Cite this